The operations of the company that produces the antiseptics Miramistin and Okomistin have been completely blocked in Russia following a court ruling, according to a lawyer. The measures affected the work of 164 medical representatives of Infamed LLC.
The manufacturer of the antiseptics Miramistin and Okomistin has been blocked from operating throughout Russia due to court-imposed restrictions, TASS reports, citing Ruben Markaryan, the lawyer representing the owners of Infamed.
According to Markaryan, the court’s decision applies to all regions of Russia where Infamed LLC operates, impacting 164 of the company’s medical representatives. The lawyer stated that the litigation is linked to Pavel Kheifits and his wife, who allegedly convinced the owner of Infamed to conclude a sham deal transferring 50% of the company shares to them at a nominal price of 7.5 million rubles, while the real value exceeded 1 billion rubles.
“A fraud complaint regarding the actions of the Kheifits family has been filed by the owners of Miramistin with the Main Directorate for Economic Security and Anti-Corruption (GUEBiPK), and the case is currently under review by the Economic Security and Anti-Corruption Department of the South-West Administrative District, Moscow Police,” said Markaryan.
Infamed LLC is a Russian company engaged in the production and wholesale distribution of the original pharmaceutical products Miramistin and Okomistin. According to the company’s website, Infamed is the exclusive manufacturer of these drugs and performs the entire production cycle — from synthesizing the active pharmaceutical ingredient to producing the final product. The lawyer noted that the company is actively involved in import substitution, including contracts with the Russian Ministry of Defense. According to SPARK data, Vitaly Nikolaev has been serving as the company’s CEO since August 2024.
According to RNC Pharma, from January to June 2025, the company produced 4.6 million units of Miramistin (including solutions and vaginal suppositories), which is 20% less than during the first two quarters of 2024. As verified by RBC, the product is still available in pharmacies in various forms.
Source: RBC, July 21, 2025
